 "Sun Pharma, Dr Reddy's, Glenmark gain even after price-fixing charges in US")
Shares of pharmaceutical companies were in focus and trading higher in otherwise subdued market even after the media reports suggested the four Indian drug makers are facing allegations of a huge price-fixing conspiracy in the US aimed at keeping prices of generic drugs artificially high.
The companies are Dr Reddy’s Laboratories (DRL), Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, and Emcure, the Business Standard report suggested. CLICK HERE TO READ FULL REPORT
All three listed pharmaceutical companies DRL, Glenmark Pharma and Sun Pharma were up more than 2% each on the National Stock Exchange (NSE). At 09:46 AM; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.8%, as compared to unchanged in Nifty 50 index at 10,441.
Besides these three stocks, Aurobindo Pharma, Cadila Healthcare and Lupin from the Nifty Pharma index, while Ajanta Pharma, Marksans Pharma, Ipca Laboratories, Sanfoi India and Biocon the non-index stocks were up 3% to 6%.
Divi’s Laboratories surged 17% to Rs 1,076, after the company said that it has been informed by the US-FDA that it will be lifting the Import Alert 66-40 and moving to close out the Warning letter issued to the company's Unit-II at Visakhapatnam. The stock zoomed 21% to Rs 1,118 on the NSE in early morning trade.
The companies are Dr Reddy’s Laboratories (DRL), Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, and Emcure, the Business Standard report suggested. CLICK HERE TO READ FULL REPORT
All three listed pharmaceutical companies DRL, Glenmark Pharma and Sun Pharma were up more than 2% each on the National Stock Exchange (NSE). At 09:46 AM; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.8%, as compared to unchanged in Nifty 50 index at 10,441.
Besides these three stocks, Aurobindo Pharma, Cadila Healthcare and Lupin from the Nifty Pharma index, while Ajanta Pharma, Marksans Pharma, Ipca Laboratories, Sanfoi India and Biocon the non-index stocks were up 3% to 6%.
Divi’s Laboratories surged 17% to Rs 1,076, after the company said that it has been informed by the US-FDA that it will be lifting the Import Alert 66-40 and moving to close out the Warning letter issued to the company's Unit-II at Visakhapatnam. The stock zoomed 21% to Rs 1,118 on the NSE in early morning trade.
| COMPANY | LATEST | PREV CLOSE | GAIN(%) |
| DIVI'S LAB. | 1071.85 | 920.30 | 16.5 |
| MARKSANS PHARMA | 49.05 | 46.40 | 5.7 |
| AJANTA PHARMA | 1256.00 | 1208.90 | 3.9 |
| GLENMARK PHARMA. | 645.10 | 621.25 | 3.8 |
| AUROBINDO PHARMA | 789.20 | 761.90 | 3.6 |
| NATCO PHARMA | 1006.00 | 974.45 | 3.2 |
| CADILA HEALTH. | 513.00 | 497.70 | 3.1 |
| IPCA LABS. | 541.50 | 525.55 | 3.0 |
| SANOFI INDIA | 4590.90 | 4458.35 | 3.0 |
| GRANULES INDIA | 142.20 | 138.20 | 2.9 |
| SEQUENT SCIEN. | 110.00 | 107.10 | 2.7 |
| LUPIN | 1055.05 | 1027.45 | 2.7 |
| BIOCON | 371.20 | 361.85 | 2.6 |
| FDC | 205.40 | 200.55 | 2.4 |
| SUN PHARMA.INDS. | 560.40 | 548.45 | 2.2 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%